A Phase 1 Study To Evaluate The Safety, Tolerability, Immunogenicity, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of PF-06342674 (M168) In Adults With Type 1 Diabetes
Phase of Trial: Phase I
Latest Information Update: 09 Nov 2016
At a glance
- Drugs PF 6342674 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Sponsors Pfizer
- 02 Nov 2016 Status changed from active, no longer recruiting to completed.
- 02 May 2016 Planned End Date changed from 1 Jun 2016 to 1 Aug 2016.
- 02 May 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Aug 2016.